{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:16:44Z","timestamp":1788553004050,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:57:22Z","timestamp":1778767042000},"page":"1127-1137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cord Blood Transplantation versus Other Donor Sources in High-Risk Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8031-6311","authenticated-orcid":false,"given":"Tatsuro","family":"Hirao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1687-7029","authenticated-orcid":false,"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jtct.2026.05.009_bib0001","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.009_bib0002","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.009_bib0003","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.009_bib0004","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ajh.27647","volume":"100","author":"Esteve","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.009_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-024-01140-5","article-title":"Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy","volume":"14","author":"Gross","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.009_bib0006","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41375-023-02119-0","article-title":"Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission","volume":"38","author":"Yanada","year":"2024","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.009_bib0007","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjh.20208","volume":"207","author":"Konuma","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.009_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-023-00953-0","article-title":"Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure","volume":"13","author":"Mozaffari Jovein","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.009_bib0009","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.009_bib0010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.009_bib0011","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41375-021-01474-0","article-title":"Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia","volume":"36","author":"Shimomura","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.009_bib0013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.009_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining The Intensity Of Conditioning Regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2026.05.009_bib0015","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/bloodadvances.2022008572","article-title":"Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia","volume":"7","author":"Fingrut","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.009_bib0016","doi-asserted-by":"crossref","unstructured":"Ho D, Imai K, G King, EA Stuart. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 42(8):1\u201328.","DOI":"10.18637\/jss.v042.i08"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.009_bib0017","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.009_bib0018","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.jtct.2026.05.009_bib0019","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2015-06-654780","article-title":"Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells","volume":"126","author":"Hiwarkar","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.009_bib0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-019-0204-x","volume":"9","author":"Baron","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.009_bib0021","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.009_bib0022","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3324\/haematol.2014.109280","article-title":"Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen","volume":"99","author":"Ruggeri","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.009_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-017-0497-9","article-title":"Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT","volume":"10","author":"Baron","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.009_bib0024","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/bjh.70099","article-title":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan","volume":"207","author":"Konuma","year":"2025","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.009_bib0025","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1182\/bloodadvances.2020001554","article-title":"Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant","volume":"4","author":"Sharma","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.009_bib0026","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","article-title":"Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy","volume":"27","author":"Dholaria","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.009_bib0027","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.009_bib0028","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.009_bib0029","doi-asserted-by":"crossref","first-page":"576.e1","DOI":"10.1016\/j.jtct.2023.06.008","article-title":"Phase II study of myeloablative 7-8\/8-matched allotransplantation with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"29","author":"El Jurdi","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:59:07Z","timestamp":1788551947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003532"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cord Blood Transplantation versus Other Donor Sources in High-Risk Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}